Serum Magnesium Level in Type 2 Diabetes Mellitus - Trial NCT06059833
Access comprehensive clinical trial information for NCT06059833 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Not yet recruiting. The study focuses on Diabetes Mellitus. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sohag University
Timeline & Enrollment
N/A
Sep 01, 2023
Sep 01, 2024
Primary Outcome
magnesium perecentage
Summary
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent
 hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions
 of insulin, or both . Chronic hyperglycemia in synergy with the other metabolic aberrations
 in patients with diabetes mellitus can cause damage to various organ systems, leading to the
 development of disabling and life-threatening health complications, most prominent of which
 are microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular complications
 leading to a 2-fold to 4-fold increased risk of cardiovascular diseases Mg2+ deficiency is
 usually identified by the measurement of serum Mg2+ concentration. Hypomagnesemia is defined
 by a serum Mg2+ concentration 0.75 mmol/L, but a deficiency due to low dietary intake in
 otherwise healthy people is uncommon. Although overt signs of clinical Mg2+ deficiency are
 not routinely recognized in the healthy population, relatively low Mg2+ intake and/or Mg2+
 status have been shown to be associated with chronic diseases, including cardiovascular
 disease, T2DM, osteoporosis, pulmonary disease, depression, migraine headaches, inflammation,
 and cancer
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06059833
Non-Device Trial

